News | December 17, 2023
Biocon Biologics recognized as an Asia IP Elite for 2023
Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list
Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list
Yesafili, received marketing authorization approval from the European Commission for the European Union
The RCSed's Court of Regents comprises a group of distinguished and accomplished individuals in their field
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
Under the terms of this agreement Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva, for its commercialization across 30 countries in Europe
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
The committee unanimously decided to confer the Lifetime Achievement Award to Kiran Mazumdar-Shaw for her monumental contributions as a global leader in biotechnology innovation and entrepreneurship
Subscribe To Our Newsletter & Stay Updated
